Insecticides (India) is currently trading at Rs. 734.15, up by 9.50 points 1.31% from its previous closing of Rs. 724.65 on the BSE.
The scrip opened at Rs. 726.05 and has touched a high and low of Rs. 734.75 and Rs. 726.05 respectively. So far 14 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 1084.65 on 28-Aug-2024 and a 52 week low of Rs. 460.50 on 19-Mar-2024.
Last one week high and low of the scrip stood at Rs. 749.10 and Rs. 712.55 respectively. The current market cap of the company is Rs. 2112.79 crore.
The promoters holding in the company stood at 72.16%, while Institutions and Non-Institutions held 14.49% and 13.36% respectively.
Insecticides (India) (IIL) has signed a memorandum of understanding (MoU) with BioPrime Agro Solutions, Pune, a research-based biological solutions firm. This alliance brings Relieve, BioPrime’s exclusive biological product, to the Indian market, furthering efforts to provide sustainable solutions for Indian agriculture.
Relieve is a unique innovative pure concentrate seaweed and botanical extract-based product. This patented biological formulation is developed with advanced biotechnology, designed to improve crop health and boost yield. Relieve will also help the crops to mitigate the damage caused by abiotic stresses such as drought, heat and salinity. By making this product accessible to Indian farmers, IIL is stepping up its commitment to offering modern and eco-friendly farming solutions.
Insecticides (India) is engaged in the manufacturing activities of agro chemicals, pesticides and technical products for agriculture purposes.
| Company Name | CMP |
|---|---|
| UPL | 665.00 |
| PI Industries | 3144.45 |
| Bayer CropScience | 4900.45 |
| Sharda Cropchem | 1109.70 |
| Sumitomo Chemical | 441.95 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: